GtoPdb Ligand ID: 7817

Synonyms: SCIO 469 hydrochloride | SCIO-469
Compound class: Synthetic organic
Comment: Talmapimod is an orally bioavailable, investigational small-molecule p38 mitogen-activated protein kinase (MAPK) inhibitor with potential immunomodulating, anti-inflammatory, and antineoplastic activities.
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 7
Topological polar surface area 65.86
Molecular weight 512.2
XLogP 4.16
No. Lipinski's rules broken 0
Canonical SMILES Fc1ccc(cc1)CN1CC(C)N(CC1C)C(=O)c1cc2c(cn(c2cc1Cl)C)C(=O)C(=O)N(C)C
Isomeric SMILES Fc1ccc(cc1)CN1C[C@@H](C)N(C[C@@H]1C)C(=O)c1cc2c(cn(c2cc1Cl)C)C(=O)C(=O)N(C)C
InChI InChI=1S/C27H30ClFN4O3/c1-16-13-33(17(2)12-32(16)14-18-6-8-19(29)9-7-18)26(35)21-10-20-22(25(34)27(36)30(3)4)15-31(5)24(20)11-23(21)28/h6-11,15-17H,12-14H2,1-5H3/t16-,17+/m0/s1
No information available.
Summary of Clinical Use
Talmapimod has been assessed in several completed Phase II clinical trials for myelodysplastic syndromes and active rheumatoid arthritis. Click here for ClinicalTrials.org's full list of completed talmapimod (SCIO-469) trials. There are no active trials registered with ClinicalTrials.org (Nov 2014).
Mechanism Of Action and Pharmacodynamic Effects
Talmapimod specifically binds to and inhibits the phosphorylation of p38 MAPK, which may result in the induction of tumor cell apoptosis, the inhibition of tumor cell proliferation, and the inhibition of tumor angiogenesis.